Prediction of Lymph Node Metastasis in Colon Cancer via Platelet to Lymphocyte Ratio and Platelet Count

Oguz Catal, Bahri Ozer and Mustafa Sit

Department of General Surgery, Abant Izzet Baysal University Hospital, Bolu, Turkey

ABSTRACT

Objective: To investigate the value of preoperative blood tests in predicting lymph node metastasis in colon cancer patients undergoing surgery.

Study Design: Observational study.

Place and Duration of Study: General Surgery Department, Bolu Abant Izzet Baysal University Medicine School, Turkey, between December 2012 and December 2018.

Methodology: In 171 colon cancer patients, preoperative inflammatory markers such as albumin, C-reactive protein (CRP), platelet, neutrophil-to-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) counts were determined.

Results: The present study albumin, CRP and NLR values were also not significantly different between the groups. PLR (p=0.008) and PLT (p=0.039) were significantly different between the lymph node groups. ROC analysis was performed for PLT and PLR for the prediction of lymph node metastasis (Group 2 and 3). Accuracy for PLT was 0.623 and for PLR was 0.65. A PLT value >321.5 was found to be 63.7% sensitive and 68.6% specific in predicting lymph node metastasis. A PLR value >155.81 was 70% sensitive and 41% specific for predicting lymph node metastasis.

Conclusion: The platelet counts and PLR values are important in predicting lymph node metastasis in colon cancer, preoperatively. Platelet and PLR values may be more specific and sensitive in predicting preoperative lymph node metastasis in colon cancer patients.

Key Words: Colon cancer, Platelet, Platelet to lymphocyte ratio (PLR), Lymph node, Metastasis, Markers of inflammation.

How to cite this article: Catal O, Ozer B, Sit M. Prediction of lymph node metastasis in colon cancer via platelet to lymphocyte ratio and platelet count. J Coll Physicians Surg Pak 2020; 30(3):250-253.
the General Surgery Clinic of Bolu Abant Izzet Baysal University were evaluated, retrospectively. Preoperative hemogram, biochemistry and postoperative pathology reports were assessed. Preoperative albumin, CRP, platelet (PLT) counts were determined. Neutrophil-lymphocyte ratio (NLR) was calculated by dividing neutrophil count to lymphocyte count. Finally, platelet / lymphocyte ratio (PLR) was determined by division of platelet count to lymphocyte count.

Using TNM classification of AJCC (Nx: Regional lymph nodes cannot be evaluated; N0: No local lymph node metastasis; N1: 1-3 metastasis in the pericolic lymph node; N2: Metastasis in 4 or more pericolytic lymph nodes; N3: Metastasis in any lymph node at a main vessel level), patients were divided into three groups according to the lymph node metastasis. There were no patients with Nx and N3 classifications. Therefore, Group 1 included patients with N0 classification, Group 2 included patients with N1, and Group 3 included patients with N2. Patients taking neoadjuvant radiotherapy, having rectal involvement or liver metastasis or undergoing emergency operation due to ileus or perforation were excluded.

Variables with normally distribution were analysed using Shapiro-Wilk test. Kruskal-Wallis and Bonferroni adjusted Dunn’s tests were used for analysing non-normally distributed continuous variables. Pearson’s correlations were calculated for assessing the relationship between the laboratory parameters and lymph node. For determining the optimum cut-off values of statistically significant variables for identifying positive lymph node receiver-operating characteristic (ROC) curve was used. All the analyses were performed with the Statistical Package for Social Sciences 25.0 for Windows (SPSS Inc., Chicago, Illinois, USA) and the results with a level of p <0.05 were considered to be significant.

RESULTS

One hundred and seventy-one colon cancer patients were included in the study. The mean age of the patients was 65.93 (16-89). The characteristics of the patients was shown in Table I.

Age, MPV, albumin, CRP and NLR values were not significantly different between the groups. PLR (p=0.008) and PLT (p=0.039) were significantly different between the groups (Table II). Post-hoc Bonferroni adjusted Dunn’s test were applied for pairwise comparisons between the groups. Platelet and PLR were found to be significantly higher in Group 3 than Group 1 (p=0.039 and p=0.008, respectively).

ROC analysis was performed for PLT and PLR for the prediction of lymph node metastasis (Group 2 and 3). Accuracy for PLT was 0.623 and accuracy for PLR was 0.659.

Table I: Classification of the patients.

<table>
<thead>
<tr>
<th>Gender</th>
<th>Group 1 (n=91)</th>
<th>Group 2 (n=44)</th>
<th>Group 3 (n=36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>56%</td>
<td>52%</td>
<td>52%</td>
</tr>
<tr>
<td>Female</td>
<td>44%</td>
<td>48%</td>
<td>48%</td>
</tr>
</tbody>
</table>

Table II: Preoperative blood test parameters.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group 1 (n=91)</th>
<th>Group 2 (n=44)</th>
<th>Group 3 (n=36)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td>3.79 ±0.56</td>
<td>3.79 ±0.58</td>
<td>3.58 ±0.58</td>
<td>0.162</td>
</tr>
<tr>
<td>CRP</td>
<td>8 (0.10 - 259.43)</td>
<td>4.9 (0 - 256)</td>
<td>8.7 (0.1 - 195.61)</td>
<td>0.224</td>
</tr>
<tr>
<td>Platelet</td>
<td>280 (117 - 746)</td>
<td>281.5 (154 - 876)</td>
<td>343.5 (170 - 627)</td>
<td>0.039</td>
</tr>
<tr>
<td>NLR</td>
<td>3.10 (1.13 - 30.55)</td>
<td>3.06 (1.10 - 18.53)</td>
<td>3.85 (1.47 - 29.88)</td>
<td>0.118</td>
</tr>
<tr>
<td>PLR</td>
<td>167.7 (41.79 - 684.4)</td>
<td>183.9 (68.13 - 494.9)</td>
<td>257.5 (86.67 - 702)</td>
<td>0.008</td>
</tr>
</tbody>
</table>

Figure 1: ROC analysis of platelet value.
A PLT value >321.5 was found to be 63.7% sensitive and 68.6% specific in predicting lymph node metastasis (Figure 1).

A PLR value >155.81 was 70% sensitive and 41% specific for predicting lymph node metastasis (Figure 2).

**DISCUSSION**

The main finding of present study was that PLR and platelet counts were associated with lymph node metastasis in colon cancer patients. In colon cancer patients, 24-41% of patients die within 5 years following surgical resection for curative purposes; besides 56-78% of patients who underwent palliative resection for colon cancer, die within two years. It is important to predict lymph node metastasis preoperatively because lymph node metastasis is the most important independent factor affecting these rates. The most important tool for preoperative staging of colon cancer is computer tomography (CT).

One of the main limitations of CT is low accuracy in lymph node staging. The presence of micrometastasis in normal sized lymph nodes and lymph node inflammation-induced growth lead to misdiagnoses in size-dependent evaluation. Various studies have been given at various rates on the preoperative prediction of CT in lymph node metastasis in colon cancer. Cademartiri et al. showed 55% sensitivity and 65% specificity for N staging. In another study, CT was 84% sensitive in evaluating lymph node metastasis in colon cancer and 54% specific.

Platelets facilitate proliferation of tumors by detaching tumor from its primary site, and masking the tumor cells from the immune surveillance. Furthermore, platelets help in metastasis; thereby, promoting tumor development to distant body parts. When the platelet counts in patients with colon cancer were examined, a strong relationship was found between the primary tumor and high platelet count in CRC patients. It is stated that they underline the predictive power of thrombocytosis in CRC patients. However, as far as the studies are concerned, not a single study has been found suggesting that the number of platelets in colon cancer can predict lymph node metastasis. In the findings of this study, significant result was found between the number of platelets and the number of positive lymph nodes. Platelet count was found to be significant in predicting lymph node metastasis or more. When the ROC analysis was performed, platelet value was found that the prediction of lymph node metastasis was 63.7%, and the specificity was 68.6% when the platelet count was higher than 321.5.

Previous studies showed that PLR is associated with prognosis of various types of cancers. Some publications on the relationship between colon cancer and PLR have shown that PLR is strongly associated with survival time, disease-free survival, and cancer-specific survival in CRC. High PLR may be a promising prognostic biomarker for CRC. In a meta-analysis, it was found that high PLR was an important biomarker for weak overall survival, disease-free survival and recurrence-free survival in patients with CRC. In a study, showing the relationship between PLR and preoperative prediction of lymph node metastasis in colon cancer, they found a significant relationship between PLR and positive lymph node ratio. In this study, there was a correlation between PLR values and positive lymph node number. ROC analysis showed that PLR value was 70% sensitive and 41% specific in predicting preoperative lymph node metastasis in colon cancer above 155.81.

In the light of this information, there was a significant difference between the groups in predicting preoperative lymph node metastasis in colon cancer patients for platelet and PLR values. Platelet and PLR values have similar results with computed tomography and sensitivity and specificity in predicting lymph node metastasis in colon cancer. Platelet and PLR values may be more specific and sensitive predicting preoperative lymph node metastasis in colon cancer patients. Especially when the number of metastatic lymph nodes is more than 3, it is more sensitive in prediction.

**CONCLUSION**

The platelet counts and PLR values are significantly important in predicting lymph node metastasis in colon cancer, preoperatively. Neoadjuvant chemotherapy can be performed in patients with metastatic lymph node positivity by examining platelet and PLR values. However, this study needs to be supported with larger patient series.
ETHICAL APPROVAL:
The Ethics Committee of Bolu Abant Izzet Baysal University Clinical Researches approved this study (Number: 414, Date: 28/12/2018).

PATIENTS’ CONSENT:
Necessary permissions were obtained from patients regarding the study.

CONFLICT OF INTEREST:
Authors declared no conflict of interest.

AUTHORS’ CONTRIBUTION:
OC: Data collection and curation, resources, validation, writing-original draft, writing-review and editing.
BO: Formal analysis, visualisation.
MS: Project administration, visualisation.

REFERENCES